Trials / Recruiting

RecruitingNCT07199309

A Mechanistic Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol

Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of MAR001 on Postprandial Lipids in Patients With Elevated Triglycerides and Remnant Cholesterol

Status: Recruiting
Phase: Phase 2
Study type: Interventional
Enrollment: 30 (estimated)

Sponsor: Marea Therapeutics · Industry
Sex: All
Age: 18 Years – 75 Years
Healthy volunteers: Not accepted

Summary

The primary objective of the study is to determine the effect of MAR001 as compared to placebo on levels of the triglycerides (TG) in the postprandial state in adults with elevated TG.

Conditions

Hypertriglyceridemia

Interventions

Type	Name	Description
DRUG	MAR001	Subcutaneous Injection
DRUG	Placebo	Subcutaneous Injection

Timeline

Start date: 2025-09-26
Primary completion: 2026-07-01
Completion: 2026-11-01
First posted: 2025-09-30
Last updated: 2025-11-06

Locations

1 site across 1 country: United States

Regulatory

FDA-regulated drug study

Source: ClinicalTrials.gov record NCT07199309. Inclusion in this directory is not an endorsement.